Allotted, called up and fully paid (all shares £0.0000005 nominal):
|
Class
|
2025
|
2025
|
2024
|
2024
|
|
No.
|
£
|
No.
|
£
|
|
Series A
|
1,425,227
|
0.71
|
636,353
|
0.32
|
|
Series B
|
455,000
|
0.23
|
910,000
|
0.46
|
|
Series C
|
90,000
|
0.05
|
90,000
|
0.05
|
|
Ordinary B1
|
455,000
|
0.23
|
910,000
|
0.46
|
|
Ordinary B2
|
90,000
|
0.05
|
90,000
|
0.05
|
|
Ordinary C1 (Growth)
|
589,661
|
0.29
|
-
|
-
|
|
Deferred
|
910,000
|
0.46
|
-
|
-
|
|
Total
|
4,014,888
|
2.01
|
2,636,353
|
1.32
|
Movements in share capital during the year:
|
Class
|
1 Oct 2024
|
Allotted in year
|
Reclassified in year
|
30 Sept 2025
|
|
No.
|
No.
|
No.
|
No.
|
|
Series A
|
636,353
|
788,874
|
-
|
1,425,227
|
|
Series B
|
910,000
|
-
|
(455,000)
|
455,000
|
|
Series C
|
90,000
|
-
|
-
|
90,000
|
|
Ordinary B1
|
910,000
|
-
|
(455,000)
|
455,000
|
|
Ordinary B2
|
90,000
|
-
|
-
|
90,000
|
|
Ordinary C1 (Growth)
|
-
|
589,661
|
-
|
589,661
|
|
Deferred
|
-
|
-
|
910,000
|
910,000
|
|
Total
|
2,636,353
|
1,378,535
|
-
|
4,014,888
|
On 28 March 2025 the company allotted 788,874 Series A shares of £0.0000005 each, in two tranches, for aggregate cash consideration of £3,477,291, of which £0.39 was credited to share capital and £3,477,290.61 to the share premium account. On the same date the company allotted 589,661 Ordinary C1 (Growth) shares of £0.0000005 each for aggregate cash consideration of £22,708, of which £0.29 was credited to share capital and £22,707.71 to the share premium account.
On 7 April 2025 the company re-converted 455,000 Series B and 455,000 Ordinary B1 shares into 910,000 Deferred shares of £0.0000005 each. The Deferred shares carry no voting or dividend rights. The re-conversion was effected at nominal value and gave rise to no movement in share capital, share premium or reserves.
There were no share buy-backs, redemptions or cancellations in the year.